X4 viruses are frequently archived in patients with long-term HIV infection but do not seem to influence the "inflamm-aging" process

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Saracino, Annalisa ^a,b   Monno, Laura ^a   Scudeller, Luigia ^c   Bruno, Giuseppe ^a   Ladisa, Nicoletta ^a   Punzi, Grazia ^a   Volpe, Anna ^a   Lagioia, Antonella ^a   Angarano, Gioacchino ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Aging; CCR5; Co receptor tropism; CXCR4; Geno2pheno; HIV proviral DNA; Inflammation markers

Indexed keywords

C REACTIVE PROTEIN; D DIMER; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTERLEUKIN 6; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; VIRUS DNA;

ADULT; AGING; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CLINICAL EVALUATION; DISEASE ASSOCIATION; DISEASE DURATION; DNA EXTRACTION; DRUG EFFECT; DRUG EXPOSURE; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; SEQUENCE ANALYSIS; TREATMENT DURATION; VIREMIA; VIRUS CLASSIFICATION; VIRUS ISOLATION; VIRUS STRAIN;

AGE FACTORS; DNA, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PREVALENCE; RECEPTORS, CCR5; RECEPTORS, CXCR4; VIRAL TROPISM;

EID: 84878161644     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-220     Document Type: Article

References (46)

1. Poveda E, Paredes R, Moreno S, Alcamí J, Córdoba J, Delgado R, Gutiérrez F, Llibre JM, García Deltoro M, Hernández-Quero J, Pulido F, Iribarren JA, García F. Genotypic Determination of HIV Tropism - Clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists. AIDS Rev 2012, 14(3):208-217.
2. Schuitemaker H, van 't Wout AB, Lusso P. Clinical significance of HIV-1 coreceptor usage. J Transl Med 2011, 9(Suppl 1):S5. 3105505, 21284904.
3. Moore JP, Kitchen SG, Pugach P, Zack JA. The CCR5 and CXCR4 coreceptors-central to understanding the transmission and pathogenesis of HIV-1 infection. AIDS Res Hum Retroviruses 2004, 20(1):111-126. 10.1089/088922204322749567, 15000703.
4. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, Wei X, Jiang C, Kirchherr JL, Gao F, Anderson JA, Ping LH, Swanstrom R, Tomaras GD, Blattner WA, Goepfert PA, Kilby JM, Saag MS, Delwart EL, Busch MP, Cohen MS, Montefiori DC, Haynes BF, Gaschen B, Athreya GS, Lee HY. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1infection. Proc Natl Acad Sci U S A 2008, 105(21):7552-7557. 10.1073/pnas.0802203105, 2387184, 18490657.
5. Margolis L, Shattock R. Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved?. Nat Rev Microbiol 2006, 4(4):312-317. 10.1038/nrmicro1387, 16541138.
6. Veazey RS, DeMaria M, Chalifoux LV, Shvetz DE, Pauley DR, Knight HL, Rosenzweig M, Johnson RP, Desrosiers RC, Lackner AA. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 1998, 280(5362):427-431. 10.1126/science.280.5362.427, 9545219.
7. Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, de Goede RE, van Steenwijk RP, Lange JM, Schattenkerk JK, Miedema F, Tersmette M. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 1992, 66(3):1354-1360. 240857, 1738194.
8. Koot M, Keet IP, Vos AH, de Goede RE, Roos MT, Coutinho RA, Miedema F, Schellekens PT, Tersmette M. Prognostic value of HIV-1 syncytiuminducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993, 118(9):681-688. 10.7326/0003-4819-118-9-199305010-00004, 8096374.
9. Karlsson I, Antonsson L, Shi Y, Oberg M, Karlsson A, Albert J, Olde B, Owman C, Jansson M, Fenyö EM. Coevolution of RANTES sensitivity and mode of CCR5 receptor use by human immunodeficiency virus type 1 of the R5 phenotype. J Virol 2004, 78(21):11807-11815. 10.1128/JVI.78.21.11807-11815.2004, 523262, 15479822.
10. Philpott S, Weiser B, Anastos K, Kitchen CM, Robison E, Meyer WA, Sacks HS, Mathur-Wagh U, Brunner C, Burger H. Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy. J Clin Invest 2001, 107(4):431-438. 10.1172/JCI11526, 199259, 11181642.
11. Skrabal K, Trouplin V, Labrosse B, Obry V, Damond F, Hance AJ, Clavel F, Mammano F. Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations. AIDS 2003, 17(6):809-814. 10.1097/00002030-200304110-00005, 12660527.
12. Galan I, Jimenez JL, Gonzalez-Rivera M, De Jose MI, Navarro ML, Ramos JT, Mellado MJ, Gurbindo MD, Bellon JM, Resino S, Cabrero E, Muñoz-Fernández MA. Virological phenotype switches under salvage therapy with lopinavir-ritonavir in heavily pretreated HIV-1 vertically infected children. AIDS 2004, 18(2):247-255. 10.1097/00002030-200401230-00014, 15075542.
13. Delobel P, Sandres-Saune K, Cazabat M, Pasquier C, Marchou B, Massip P, Izopet J. R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2005, 38(4):382-392. 10.1097/01.qai.0000152835.17747.47, 15764954.
14. Briz V, Poveda E, del Mar GM, Martin-Carbonero L, Gonzalez-Gonzalez R, Soriano V. Impact of antiretroviral therapy on viral tropism in HIV-infected patients followed longitudinally for over 5 years. J Antimicrob Chemother 2008, 61(2):405-410.
15. Saracino A, Monno L, Cibelli DC, Punzi G, Brindicci G, Ladisa N, Tartaglia A, Lagioia A, Angarano G. Co-receptor switch during HAART is independent of virological success. J Med Virol 2009, 81(12):2036-2044. 10.1002/jmv.21598, 19856465.
16. Coakley E, Petropoulos CJ, Whitcomb JM. Assessing chemokine coreceptor usage in HIV. Curr Opin Infect Dis 2005, 18(1):9-15. 10.1097/00001432-200502000-00003, 15647694.
17. Hunt PW, Harrigan PR, Huang W, Bates M, Williamson DW, McCune JM, Price RW, Spudich SS, Lampiris H, Hoh R, Leigler T, Martin JN, Deeks SG. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis 2006, 194(7):926-930. 10.1086/507312, 16960780.
18. Wilkin TJ, Su Z, Kuritzkes DR, Hughes M, Flexner C, Gross R, Coakley E, Greaves W, Godfrey C, Skolnik PR, Timpone J, Rodriguez B, Gulick RM. HIV type 1 chemokine coreceptor use among antiretroviral- experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 2007, 44(4):591-595. 10.1086/511035, 17243065.
19. Melby T, Despirito M, Demasi R, Heilek-Snyder G, Greenberg ML, Graham N. HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response. J Infect Dis 2006, 194(2):238-246. 10.1086/504693, 16779731.
20. Nixon DE, Landay AL. Biomarkers of immune dysfunction in HIV. Curr Opin HIV AIDS 2010, 5(6):498-503. 10.1097/COH.0b013e32833ed6f4, 3032605, 20978393.
21. High KP, Brennan-Ing M, Clifford DB, Cohen MH, Currier J, Deeks SG, Deren S, Effros RB, Gebo K, Goronzy JJ, Justice AC, Landay A, Levin J, Miotti PG, Munk RJ, Nass H, Rinaldo CR, Shlipak MG, Tracy R, Valcour V, Vance DE, Walston JD, Volberding P. HIV and Aging: State of Knowledge and Areas of Critical Need for Research. A Report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr 2012, 60(Suppl 1):S1-S18.
22. Boulware DR, Hullsiek KH, Hullsiek KH, Puronen CE, Rupert A, Baker JV, French MA, Bohjanen PR, Novak RM, Neaton JD, Sereti I, INSIGHT Study Group Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis 2011, 203(11):1637-1646. 10.1093/infdis/jir134, 3096784, 21592994, INSIGHT Study Group.
23. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Neuhaus J, Nixon D, Paton NI, Neaton JD, INSIGHT SMART Study Group Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008, 5(10):e203. 10.1371/journal.pmed.0050203, 2570418, 18942885, INSIGHT SMART Study Group.
24. Duprez DA, Neuhaus J, Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Nixon D, Paton NI, Prineas RJ, Neaton JD, for the INSIGHT SMART Study Group Inflammation, Coagulation and Cardiovascular Disease in HIV-Infected Individuals. PLoS One 2012, 7(9):e44454. 10.1371/journal.pone.0044454, 3438173, 22970224, for the INSIGHT SMART Study Group.
25. Armah KA, McGinnis K, Baker J, Gibert C, Butt AA, Bryant KJ, Goetz M, Tracy R, Oursler KK, Rimland D, Crothers K, Rodriguez-Barradas M, Crystal S, Gordon A, Kraemer K, Brown S, Gerschenson M, Leaf DA, Deeks SG, Rinaldo C, Kuller LH, Justice A, Freiberg M. HIV Status, Burden of Comorbid Disease, and Biomarkers of Inflammation, Altered Coagulation, and Monocyte Activation. Clin Infect Dis 2012, 55(1):126-136. 10.1093/cid/cis406, 22534147.
26. Neuhaus J, Jacobs DR, Baker JV, Calmy A, Duprez D, La Rosa A, Kuller LH, Pett SL, Ristola M, Ross MJ, Shlipak MG, Tracy R, Neaton JD. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010, 201(12):1788-1795. 10.1086/652749, 2872049, 20446848.
27. Lifson AR, Belloso WH, Davey RT, Duprez D, Gatell JM, Hoy JF, Krum EA, Nelson R, Pedersen C, Perez G, Price RW, Prineas RJ, Rhame FS, Sampson JH, Worley J, for the INSIGHT Study Group Development of Diagnostic Criteria for Serious Non-AIDS Events in HIV Clinical Trials. HIV Clin Trials 2010, 11(4):205-219. 10.1310/hct1104-205, 3109979, 20974576, for the INSIGHT Study Group.
28. Verhofstede C, Brudney D, Reynaerts J, Vaira D, Fransen K, De Bel A, Seguin-Devaux C, De Wit S, Vandekerckhove L, Geretti AM. Concordance between HIV-1 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA. HIV Med 2011, 12(9):544-552. 10.1111/j.1468-1293.2011.00922.x, 21518222.
29. Monno L, Saracino A, Scudeller L, Punzi G, Brindicci G, Altamura M, Lagioia A, Ladisa N, Angarano G. Impact of mutations outside the V3 region on coreceptor tropism phenotypically assessed in patients infected with HIV-1 subtype B. Antimicrob Agents Chemother 2011, 55(11):5078-5084. 10.1128/AAC.00743-11, 3195025, 21876051.
30. Brieu N, Portalès P, Carles MJ, Corbeau P. Interleukin-7 induces HIV type 1 R5-to-X4 switch. Blood 2011, 117(6):2073-2074. 10.1182/blood-2010-10-311860, 21310936.
31. Brumme ZL, Goodrich J, Mayer HB, Brumme CJ, Henrick BM, Wynhoven B, Asselin JJ, Cheung PK, Hogg RS, Montaner JS, Harrigan PR. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naïve individuals. J Infect Dis 2005, 192(3):466-474. 10.1086/431519, 15995960.
32. Moyle GJ, Wildfire A, Mandalia S, Mayer H, Goodrich J, Whitcomb J, Gazzard BG. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005, 191(6):866-872. 10.1086/428096, 15717260.
33. Cooper DA, Heera J, Goodrich J, Tawadrous M, Saag M, Dejesus E, Clumeck N, Walmsley S, Ting N, Coakley E, Reeves JD, Reyes-Teran G, Westby M, Van Der Ryst E, Ive P, Mohapi L, Mingrone H, Horban A, Hackman F, Sullivan J, Mayer H. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010, 201(6):803-813. 10.1086/650697, 20151839.
34. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H, MOTIVATE Study Teams Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008, 359(14):1429-1441. 10.1056/NEJMoa0803152, 3078519, 18832244, MOTIVATE Study Teams.
35. Soulié C, Fourati S, Lambert-Niclot S, Malet I, Wirden M, Tubiana R, Valantin MA, Katlama C, Calvez V, Marcelin AG. Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists. J Antimicrob Chemother 2010, 65(4):749-751. 10.1093/jac/dkq029, 20150182.
36. Seclén E, Gonzalez M, De Mendoza G, Soriano V, Poveda E. Dynamics of HIV tropism under suppressive antiretroviral therapy: implications for tropism testing in subjects with undetectable viraemia. J Antimicrob Chemother 2010, 65:1493-1496. 10.1093/jac/dkq156, 20488982.
37. Verhofstede C, Vandekerckhove L, Eygen VV, Demecheleer E, Vandenbroucke I, Winters B, Plum J, Vogelaers D, Stuyver L. CXCR4-using HIV type 1 variants are more commonly found in peripheral blood mononuclear cell DNA than in plasma RNA. J Acquir Immune Defic Syndr 2009, 50(2):126-136. 10.1097/QAI.0b013e31819118fa, 19131897.
38. Monno L, Scudeller L, Ladisa N, Maggi P, Angarano G. A greater prevalence of X4 viruses in HIV type 1 intravenous drug users reflects a "CD4+ effect". AIDS Res Hum Retroviruses 2011, 27(10):1029-1031. 10.1089/aid.2010.0217, 21182458.
39. Peeters M, Vincent R, Perret JL, Lasky M, Patrel D, Liegeois F, Courgnaud V, Seng R, Matton T, Molinier S, Delaporte E. Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: Syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J Acquir Immune Defic Syndr Hum Retrovirol 1999, 20(2):115-121. 10.1097/00042560-199902010-00002, 10048897.
40. Scherrer AU, Ledergerber B, von Wyl V, Böni J, Yerly S, Klimkait T, Bürgisser P, Rauch A, Hirschel B, Cavassini M, Elzi L, Vernazza PL, Bernasconi E, Held L, Günthard HF, Swiss HIV Cohort Study Improved virological outcome in white patients infected with HIV-1 non-B subtypes compared to subtype B. Clin Infect Dis 2011, 53(11):1143-1152. 10.1093/cid/cir669, 21998284, Swiss HIV Cohort Study.
41. Monno L, Scudeller L, Saracino A, Santoro CR, Lagioia A, Ladisa N, Angarano G. Improved Virological Outcome in Non-B Patients: A Possible Role for Baseline Coreceptor Tropism. Clin Infect Dis 2012, 55(1):165-167.
42. Balasubramanian A, Ganju RK, Groopman JE. Signal transducer and activator of transcription factor 1 mediates apoptosis induced by hepatitis C virus and HIV envelope proteins in hepatocytes. J Infect Dis 2006, 194(5):670-681. 10.1086/505708, 16897667.
43. Bruno R, Galastri S, Sacchi P, Cima S, Caligiuri A, DeFranco R, Milani S, Gessani S, Fantuzzi L, Liotta F, Frosali F, Antonucci G, Pinzani M, Marra F. gp120 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis. Gut 2010, 59(4):513-520. 10.1136/gut.2008.163287, 19736361.
44. Lin W, Weinberg EM, Tai AW, Peng LF, Brockman MA, Kim KA, Kim SS, Borges CB, Shao RX, Chung RT. HIV increases HCV replication in a TGF-beta1-dependent manner. Gastroenterology 2008, 134(3):803-811. 10.1053/j.gastro.2008.01.005, 18325393.
45. Bastard JP, Soulié C, Fellahi S, Ham-Boukobza S, Simon A, Katlama C, Calvez V, Marcelin AG, Capeau J. Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patients. Antivir Ther 2012, 17(5):915-919. 10.3851/IMP2093, 22436412.
46. Vandekerckhove LPR, Wensing AMJ, Kaiser R, Brun-Vézinet F, Clotet B, De Luca A, Dressler S, Garcia F, Geretti AM, Klimkait T, Korn K, Masquelier B, Perno CF, Schapiro JM, Soriano V, Sönnerborg A, Vandamme AM, Verhofstede C, Walter H, Zazzi M, Boucher CAB. European guidelines on the clinical management of HIV-1 tropism testing. Lancet Inf Dis 2011, 11(5):394-407.